AACR19: could HDAC inhibition combat anti-PD-1 resistance in melanoma patients?

Written by Jade Parker, Senior Editor

According to results from the ENCORE 601 Phase Ib/II clinical trial, a combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda®) exhibits clinical responses in melanoma patients who had progressed on prior anti-PD-1 treatment. The findings were recently presented at the AACR Annual Meeting (March 29 – April 3, Atlanta, GA, USA). “Our results suggest that this combination may be an active regimen for patients who never responded to or progressed during treatment with PD-1 inhibitors.” In this single-arm trial, patients were treated with 5mg of entinostat once per week in conjunction with 200mg...

To view the full article, please register now for access

It's completely free